- US stocks opened higher
- Jobless claims fell unexpectedly
- Biogen (BIIB.US) stock plunges as Samsung denies report of takeover talks
US indices launched today's session higher, with Dow Jones and S&P500 extended upward move after closing at all-time highs yesterday, as the “Santa Claus rally" continues despite thin volumes and rising number of COVID-19 cases. On the data front, initial jobless claims surprised on the upside and dropped below 200k.
Yesterday US2000 failed to break below major support at 2240 pts which is strengthened by 61.8% Fibonacci retracement of the upward wave launched in August 2021. Index launched today's session higher, however only a decisive break above the 200 SMA (red line ) and 100 EMA (purple line) may initiate a bigger upward move. On the other hand should break below the aforementioned support occur, downward move may accelerate towards 2185 pts level. Source: xStation5
Start investing today or test a free demo
Create account Try a demo Download mobile app Download mobile appCompany news:
Biogen (BIIB.US) stock fell 6.5% before the opening bell after Samsung denied a report in the Korea Economic Daily publication that it is willing to acquire Biogen and combine it with its biotech unit.
Biogen (BIIB.US) stock rose sharply yesterday following acquisition news, however buyers failed to stay above 200 SMA (red line) and today price pulled back following Samsung’s comments. If current sentiment prevails, the price may move towards the support zone around $232.00. Source: xStation5
Tesla (TSLA.US) stock dropped slightly in premarket after the transport safety body NHTSA disclosed that the EV-maker is recalling 475,318 vehicles over two separate safety-related issues.
JetBlue (JBLU.US) stock fell 1% in premarket after the airline withdraw nearly 1,300 flights from its schedule through January 13, due to rising number of Covid-19 infections among pilots and flight attendants.
Johnson & Johnson (JNJ.US) announced that a booster shot of its Covid-19 vaccine turned out to be 85% effective in preventing hospitalizations in a South African study, which has yet to be peer-reviewed.
This content has been created by XTB S.A. This service is provided by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, entered in the register of entrepreneurs of the National Court Register (Krajowy Rejestr Sądowy) conducted by District Court for the Capital City of Warsaw, XII Commercial Division of the National Court Register under KRS number 0000217580, REGON number 015803782 and Tax Identification Number (NIP) 527-24-43-955, with the fully paid up share capital in the amount of PLN 5.869.181,75. XTB S.A. conducts brokerage activities on the basis of the license granted by Polish Securities and Exchange Commission on 8th November 2005 No. DDM-M-4021-57-1/2005 and is supervised by Polish Supervision Authority.
